Quick Takeaways
- Canaan XI L.P. filed SCHEDULE 13G/A for Tyra Biosciences, Inc. COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA).
- Disclosed ownership: 1.4%.
- Date of event: 31 Mar 2026.
Canaan XI L.P. - 31 Mar 2026 SCHEDULE 13G/A Report for Tyra Biosciences, Inc. COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA)
- Filing Manager
- Canaan XI L.P.
- Reporting Manager
- Canaan XI L.P.
- Symbol
- TYRA
- Shares outstanding
- 53,571,429 shares
- Disclosed Ownership
- 750,000 shares
- Ownership
- 1.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 24 Apr 2026, 16:15:04 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 13 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Canaan XI L.P. disclosed 1.4% ownership in Tyra Biosciences, Inc. COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA) on 31 Mar 2026."
What Changed
- Previous schedule filing date: 13 Feb 2026.
- Current filing was accepted on 24 Apr 2026, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Canaan XI L.P. | 1.4% | 750,000 | 750,000 | 0 | /s/ Nancy Levenson | Nancy Levenson, Attorney-in-Fact | |
| Canaan Partners XI LLC | 1.4% | 750,000 | 750,000 | 0 | /s/ Nancy Levenson | Nancy Levenson, Attorney-in-Fact | |
| Canaan 2020+ Co-Investment L.P. - Series 7 | 0% | 0 | 0 | 0 | /s/ Nancy Levenson | Nancy Levenson, Attorney-in-Fact | |
| Canaan Partners 2020+ Co-Investment LLC | 0% | 0 | 0 | 0 | /s/ Nancy Levenson | Nancy Levenson, Attorney-in-Fact |